Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: J Immunol. 2015 May 13;194(12):5926–5936. doi: 10.4049/jimmunol.1500385

Figure 1. Study design and evaluation of vaccine efficacy.

Figure 1

A) Analysis of 6OXY-specific B cells was performed either in spleen biopsy or blood samples before and after immunization with 6OXY-KLH or KLH in alum on days 0, 14 and 28 (n=12 each group). B-E) Shown data from a BALB/c mice cohort that received partial splenectomy a week after the third immunization. On day 35, 2.25 mg/kg s.c. oxycodone was administered to mice for testing vaccine's effect on oxycodone distribution to serum and to the brain, and on oxycodone nociception. B) 6OXY-specific serum IgG titers in mice immunized with 6OXY-KLH or unconjugated KLH. Effect of immunization on: oxycodone distribution to C) serum and D) the brain, and E) oxycodone antinociception. The maximum possible effect (MPE) represents hind paw lifts on a hot plate (25). *p<0.05 and ***p<0.001; brackets indicate group differences.